Psychemedics (PMD)
(Delayed Data from NSDQ)
$2.34 USD
+0.01 (0.43%)
Updated Sep 20, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Psychemedics Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 22 | 25 | 25 | 21 | 38 |
Cost Of Goods | 14 | 16 | 15 | 16 | 21 |
Gross Profit | 8 | 9 | 10 | 5 | 16 |
Selling & Adminstrative & Depr. & Amort Expenses | 11 | 10 | 10 | 11 | 13 |
Income After Depreciation & Amortization | -3 | -1 | 0 | -6 | 3 |
Non-Operating Income | 1 | 0 | 5 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -3 | -1 | -1 | -6 | 3 |
Income Taxes | 1 | 0 | 0 | -2 | 2 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -4 | -1 | -1 | -4 | 2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -4 | -1 | -1 | -4 | 2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | 2 | 4 | -2 | 6 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 4 | 4 | 3 |
Income After Depreciation & Amortization | -3 | -1 | 0 | -6 | 3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.74 | 5.71 | 5.54 | 5.51 | 5.51 |
Diluted EPS Before Non-Recurring Items | -0.72 | -0.19 | -0.12 | -0.70 | 0.44 |
Diluted Net EPS (GAAP) | -0.72 | -0.19 | -0.12 | -0.70 | 0.28 |
Fiscal Year end for Psychemedics Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 4.73 | 5.36 | 5.00 | 5.70 | 5.54 |
Cost Of Goods | 3.18 | 3.24 | 2.94 | 3.61 | 3.48 |
Gross Profit | 1.55 | 2.12 | 2.06 | 2.09 | 2.06 |
SG&A, R&D, and Dept/Amort Expenses | 2.45 | 2.69 | 2.93 | 3.20 | 2.48 |
Income After SG&A, R&D, and Dept/Amort Expenses | -0.90 | -0.57 | -0.87 | -1.11 | -0.42 |
Non-Operating Income | 0.00 | 0.00 | 0.01 | 0.00 | 0.50 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -0.90 | -0.57 | -0.88 | -1.11 | -0.92 |
Income Taxes | -0.07 | 0.12 | 0.07 | 0.99 | -0.20 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -0.83 | -0.69 | -0.94 | -2.10 | -0.73 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -0.83 | -0.69 | -0.94 | -2.10 | -0.73 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 5.82 | 5.81 | 5.91 | 5.58 | 5.59 |
Diluted EPS Before Non-Recurring Items | -0.14 | -0.12 | -0.16 | -0.36 | -0.13 |
Diluted Net EPS (GAAP) | -0.14 | -0.12 | -0.16 | -0.36 | -0.13 |